Cholestrol to Vitamin D
Our approach aims to optimize the body's natural cholesterol-to-vitamin D conversion pathway, potentially offering a more effective solution than existing treatments.
Most humans are suffering from Vit D deficiency or insufficiency.
Vitamin D deficiency represents a widespread global health challenge, with a crucial yet often overlooked connection to cholesterol metabolism. While cholesterol serves as a natural precursor to vitamin D in the body, many individuals suffer from both vitamin D deficiency and cholesterol imbalances - specifically elevated LDL ("bad") cholesterol and reduced HDL ("good") cholesterol levels.
This imbalance can lead to serious health complications, including compromised bone density, increased risk of depression, and cardiovascular issues.
Current solutions are suboptimal: traditional cholesterol-lowering medications like statins may accelerate neuromuscular aging, while vitamin D supplements have shown limited effectiveness compared to the body's natural vitamin D synthesis.
Where we come in:
Moodforest has developed an innovative protocol that addresses this complex metabolic relationship. Our approach aims to optimize the body's natural cholesterol-to-vitamin D conversion pathway, potentially offering a more effective solution than existing treatments.
We are now seeking investment to advance this promising protocol through optimization, refinement, and validation in clinical trials.
The Study
Phase 1
Groups (each 30 M + 30 F)
A: Normal Control
B: Control Group on Human Assisted Protocol
C: Test Group on App Assisted Protocol
D: Test Group on Device Assisted Protocol
Phase 3
Groups (each 15 M + 15 F)
A: Normal Control
B: Control Group on Statins
C: Control Group on Vit D supplementation
D: Test Group on Protocol 1
E: Test Group on Protocol 2
F: Test Group on Protocol 3
Multicentric global trial on App and Device assisted Protocols .
Phase 2
Time & Budget
1 year | $300k
Study:
Phase 1
Apr – Jun 2025 | $60k
Phase 2
Oct – Dec 2025 | $75k
Phase 3
Jan – Mar 2026 | $100k
Development:
AI assisted App
Apr – Sep 2025 | $15k
AI assisted Device
Apr – Sep 2025 | $50k
Research Team
Madhur Anand
Co-founder | Coach
Clinical Psychologist
Vaidehi Phagre
Program Manager
Creative Lead and Odissi Artiste
Dr. Elisa Pierella
Partnerships & Research
PhD Gut Microbiome, UCLan, UK
Prof. Geertjaan Overbeek
Research Advisor
Research Director, University of Amsterdam
Dr. Jitendra K. Saraf
Medical Advisor
Senior Physician, Govt. of MP
Lily Yang
Program Associate
Youth Studies Master's, University of Amsterdam
Sidhant Mehra
Marketing Advisor
Structure - Marketing Agency
Dr. Vipin Gupta
Program Advisor
Co-founder, Sehatvan & Inventi Journals
Dr. SK Goel
Coordinator Clinical Research
Former Dean, AIIMS Bhopal
How to Support?
1.
Spread the word
2.
Develop our App/ Device
3.
Volunteer for the Study
Market Size
-
> 1 billion humans suffer from Vit D deficiency, hypercholesterolemia, depression or anxiety.
-
1/3 human deaths are caused by cardiovascular diseases.
Implementation
-
In company owned spaces.
-
Through centrally controlled Apps and Devices.
Moat
-
Patents being filed.
-
Will maintain the frontrunner position through strong branding and intensive research.
4. Fund us
The Study requires $300k
We have already secured $52k = looking for $248k)
-
Grants: $500 or more.
-
Investments
-
Series A (2025): $20k to $300k for 0.5% to 7.5% stake.2. Series B (2026): $300k to $3m for 0.5% to 7.5% stake
Vitamin D deficiency represents a significant global health challenge, affecting populations across all ages and ethnicities. The distribution and severity of this deficiency show notable variations based on geographical location, age demographics, and gender.
-
Approximately 1 billion people worldwide experience low vitamin D levels
-
In several countries, including India, Iran, and Turkey, vitamin D deficiency rates exceed 90% of the population
-
People residing in high-latitude regions show increased prevalence of vitamin D deficiency
-
Women demonstrate higher rates of vitamin D deficiency compared to men
